Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system (CNS) metastases. We present results of a subgroup analysis of Korean patients from the pooled data of two global phase II trials: AURA extension (NCT01802632) and AURA2 (NCT02094261). Materials and Methods Enrolled patients had EGFR T790M-positive NSCLC and disease progression during or after EGFR-TKI therapy. Patients received osimertinib 80 mg orally once daily until disease progression. The primary endpoint was objective response rate (ORR). Results In total, 66 Korean patients received osimertinib treatment with a median treatment duration of 19 months. In the evaluable-for-response population (n=62), ORR was 74% (95% confidence interval [CI], 61.5 to 84.5) and median duration of response was 9.8 months (95% CI, 7.1 to 16.8). In the full analysis set (n=66), median progression-free survival was 10.9 months (95% CI, 8.3 to 15.0; data cutoff November 1, 2016), and median overall survival was 29.2 months (95% CI, 24.8 to 35.7; data cutoff May 1, 2018). Eight patients with CNS metastases were evaluable for response, none of whom showed CNS progression. The most common adverse events were rash (53%), cough (33%), paronychia, diarrhea, and decreased appetite (each 32%). Conclusion Efficacy and safety profiles of osimertinib in this subgroup are consistent with the global phase II pooled population, which supports osimertinib as a recommended treatment for Korean patients with T790M positive NSCLC.
Abstract
Purpose Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system (CNS) metastases. We present results of a subgroup analysis of Korean patients from the pooled data of two global phase II trials: AURA extension (NCT01802632) and AURA2 (NCT02094261). Materials and Methods Enrolled patients had EGFR T790M-positive NSCLC and disease progression during or after EGFR-TKI therapy. Patients received osimertinib 80 mg orally once daily until disease progression. The primary endpoint was objective response rate (ORR). Results In total, 66 Korean patients received osimertinib treatment with a median treatment duration of 19 months. In the evaluable-for-response population (n=62), ORR was 74% (95% confidence interval [CI], 61.5 to 84.5) and median duration of response was 9.8 months (95% CI, 7.1 to 16.8). In the full analysis set (n=66), median progression-free survival was 10.9 months (95% CI, 8.3 to 15.0; data cutoff November 1, 2016), and median overall survival was 29.2 months (95% CI, 24.8 to 35.7; data cutoff May 1, 2018). Eight patients with CNS metastases were evaluable for response, none of whom showed CNS progression. The most common adverse events were rash (53%), cough (33%), paronychia, diarrhea, and decreased appetite (each 32%). Conclusion Efficacy and safety profiles of osimertinib in this subgroup are consistent with the global phase II pooled population, which supports osimertinib as a recommended treatment for Korean patients with T790M positive NSCLC.
참고문헌 (22)
- Tan DS, "The International Association for the Study of Lung Cancer Consensus Statement on optimizing management of EGFR mutation-positive non-small cell lung cancer : status in 2016", J Thorac Oncol, 11, pp.946~963 (2016)
- Hanna N, "Systemic therapy for stage IV non-small-cell lung cancer : American Society of Clinical Oncology Clinical Practice Guideline update", J Clin Oncol, 35, pp.3484~3515 (2017)
- Planchard D, "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 29(Suppl 4), pp.iv192~iv237 (2018)
- Rosell R, "Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13, pp.239~246 (2012)
- Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Sequist LV, "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations", J Clin Oncol, 31, pp.3327~3334 (2013)
- Wang ZF, "Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R : a systematic review and meta-analysis", BMC Cancer, 18, pp.148~ (2018)
- Cross DA, "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer", Cancer Discov, 4, pp.1046~1061 (2014)
- Soria JC, "Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
- Wu YL, "CNS efficacy of osimertinib in patients with T790Mpositive advanced non-small-cell lung cancer : data from a randomized phase III trial(AURA3)", J Clin Oncol, 36, pp.2702~2709 (2018)
- Reungwetwattana T, "CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-smallcell lung cancer", J Clin Oncol, 36, pp.3290~3297 (2018)
- Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
- Yang JC, "Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer : AURA study phase II extension component", J Clin Oncol, 35, pp.1288~1296 (2017)
- Goss G, "Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer(AURA2) : a multicentre, open-label, single-arm, phase 2 study", Lancet Oncol, 17, pp.1643~1652 (2016)
- Ahn MJ, "Osimertinib in patients with T790M mutationpositive, advanced non-small cell lung cancer : long-term follow-up from a pooled analysis of 2 phase 2 studies", Cancer, 125, pp.892~901 (2019)
- Mok T, "CNS response to osimertinib in patients(pts)with T790M-positive advanced NSCLC : data from a randomized phase III trial(AURA3)", J Clin Oncol, 35(15 Suppl), pp.9005~ (2017)
- Novello S, "Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol., 27(suppl 5), pp.v1~v27 (2016)
- Douillard JY, "First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients : a phase-IV, open-label, singlearm study", Br J Cancer, 110, pp.55~62 (2014)
- Shigematsu H, "Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers", J Natl Cancer Inst, 97, pp.339~346 (2005)
- 이상화, "Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey", Journal of Pathology and Translational Medicine, 49(6), pp.481~488 (2015), 대한병리학회[DOI]
- Goss G, "CNS response to osimertinib in patients with T790Mpositive advanced NSCLC : pooled data from two phase II trials", Ann Oncol, 29, pp.687~693 (2018)
- Rangachari D, "Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers", Lung Cancer, 88, pp.108~111 (2015)